Journal
CLINICAL GENITOURINARY CANCER
Volume 13, Issue 4, Pages 271-279Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clgc.2015.01.008
Keywords
Chemotherapy; Hormonal therapy; Immunotherapy; Prostate cancer; Radiopharmaceuticals
Categories
Ask authors/readers for more resources
Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patients develop castration-resistant prostate cancer, several new therapeutic strategies are available. Large trials have shown a survival benefit for patients treated with sipuleucel-T, docetaxel, cabazitaxel, abiraterone, enzalutamide, or radium-223. Along with these new available treatment options, the sequence of applying them has become a serious matter of debate. In this review we provide an overview of current systemic treatment options for metastatic prostate cancer and propose considerations to optimally sequence registered new therapies. In addition, we hypothesize on improvement of outcome with potential combination strategies. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available